On Friday, Cooper Tire & Rubber Co (NYSE:CTB)’s shares declined -13.13% to $36.91.
Cooper Tire & Rubber Co (CTB) declared that net income attributable to Cooper Tire & Rubber Company was $41 million, or $0.69 per share, contrast with $45 million, or $0.71 per share, last year. Net sales were $663 million contrast with $796 million in the first quarter of 2014. The sales decline was more than attributable to the absence of CCT, the company’s former joint venture in China, which was divested in the fourth quarter of 2014. CCT contributed $157 million to net sales, net of intercompany eliminations, in the first quarter of 2014. Not taking into account CCT, first quarter 2015 sales rose 4 percent as a result of higher unit volume of $35 million, which was partially offset by negative foreign exchange of $7 million.
Cooper Tire & Rubber Company, together with its auxiliaries, manufactures and markets replacement tires worldwide. The company operates in two segments, Americas Tire Operations and International Tire Operations.
Ibio Inc (NYSEMKT:IBIO)’s shares dropped -11.65% to $0.910.
Ibio Inc (IBIO) has engaged Caliber Biotherapeutics LLC to scale-up and produce materials for clinical development of the first of iBio’s proprietary anti-fibrosis products, IBIO-CFB03. Caliber’s production will be used for IND-enabling toxicology studies and initial human clinical trials of IBIO-CFB03.
iBio, Inc., a biotechnology company, focuses on the commercialization of its proprietary plant-based protein expression technologies in the United States and internationally. Its proprietary technologies comprise iBioLaunch, a transformative platform technology for the development and production of therapeutic proteins and vaccines; and iBioModulator, a technology platform that enhances the potency and duration of the effect of prophylactic and therapeutic vaccines.
At the end of Friday’s trade, TRANSFORM LOGIC CORP (OTCMKTS:TLOG)‘s shares dipped -10.34% to $3.90.
TRANSFORM LOGIC CORP (TLOG) a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, recently declared that it has commenced an underwritten public offering of shares of its common stock. All of the shares in the offering are to be sold by TetraLogic.
TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. Its clinical-stage product candidate, Birinapant, is in Phase II clinical trial administered with azacitidine for the treatment of myelodysplastic syndromes.
Cytokinetics, Inc. (NASDAQ:CYTK), ended its Friday’s trading session with -10.17% loss, and closed at $5.65.
Cytokinetics, Inc. (CYTK) declared that it is planned to host its Research and Development Day on Tuesday, May 12, 2015. The event is planned to take place from 8:00 AM - 11:00 AM Eastern Time at the New York Grand Hyatt Hotel in New York, New York and will be simultaneously webcast. Representatives of Cytokinetics` senior administration team will be joined by expert clinicians to provide updates regarding the company`s discovery and development programs counting recent progress, milestones and other commentary.
Cytokinetics, Incorporated, a clinical stage biopharmaceutical company, focuses on the discovery and development of novel small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
